Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Altered Lipid Tumor Environment and Its Potential Effects on NKT Cell Function in Tumor Immunity.

Tiwary S, Berzofsky JA, Terabe M.

Front Immunol. 2019 Sep 18;10:2187. doi: 10.3389/fimmu.2019.02187. eCollection 2019. Review.

PMID:
31620124
2.

[Usefulness of Post-processing Scatter Correction in Portable Abdominal Radiography Using a Low Ratio Anti-scatter Grid].

Ichikawa H, Yamada Y, Sawane Y, Terabe M, Ono T, Nishikawa M, Yamaguchi M, Shimada H.

Nihon Hoshasen Gijutsu Gakkai Zasshi. 2019;75(9):885-891. doi: 10.6009/jjrt.2019_JSRT_75.9.885. Japanese.

3.

High-fidelity detection and sorting of nanoscale vesicles in viral disease and cancer.

Morales-Kastresana A, Musich TA, Welsh JA, Telford W, Demberg T, Wood JCS, Bigos M, Ross CD, Kachynski A, Dean A, Felton EJ, Van Dyke J, Tigges J, Toxavidis V, Parks DR, Overton WR, Kesarwala AH, Freeman GJ, Rosner A, Perfetto SP, Pasquet L, Terabe M, McKinnon K, Kapoor V, Trepel JB, Puri A, Kobayashi H, Yung B, Chen X, Guion P, Choyke P, Knox SJ, Ghiran I, Robert-Guroff M, Berzofsky JA, Jones JC.

J Extracell Vesicles. 2019 Jun 19;8(1):1597603. doi: 10.1080/20013078.2019.1597603. eCollection 2019.

4.

Improving solutions by embedding larger subproblems in a D-Wave quantum annealer.

Okada S, Ohzeki M, Terabe M, Taguchi S.

Sci Rep. 2019 Feb 14;9(1):2098. doi: 10.1038/s41598-018-38388-4.

5.

Tissue-Specific Roles of NKT Cells in Tumor Immunity.

Terabe M, Berzofsky JA.

Front Immunol. 2018 Aug 15;9:1838. doi: 10.3389/fimmu.2018.01838. eCollection 2018. Review.

6.

Optimization of neural networks via finite-value quantum fluctuations.

Ohzeki M, Okada S, Terabe M, Taguchi S.

Sci Rep. 2018 Jul 2;8(1):9950. doi: 10.1038/s41598-018-28212-4.

7.

Differential Regulation of T-cell mediated anti-tumor memory and cross-protection against the same tumor in lungs versus skin.

O'Konek JJ, Ambrosino E, Bloom AC, Pasquet L, Massilamany C, Xia Z, Terabe M, Berzofsky JA.

Oncoimmunology. 2018 Apr 9;7(7):e1439305. doi: 10.1080/2162402X.2018.1439305. eCollection 2018.

8.

Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells.

Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M, Agdashian D, Terabe M, Berzofsky JA, Fako V, Ritz T, Longerich T, Theriot CM, McCulloch JA, Roy S, Yuan W, Thovarai V, Sen SK, Ruchirawat M, Korangy F, Wang XW, Trinchieri G, Greten TF.

Science. 2018 May 25;360(6391). pii: eaan5931. doi: 10.1126/science.aan5931.

9.

IL13Rα2 expression identifies tissue-resident IL-22-producing PLZF+ innate T cells in the human liver.

Paquin-Proulx D, Greenspun BC, Pasquet L, Strunz B, Aleman S, Falconer K, Terabe M, Berzofsky JA, Sandberg JK, Melum E, Nixon DF, Björkström NK.

Eur J Immunol. 2018 Aug;48(8):1329-1335. doi: 10.1002/eji.201747334. Epub 2018 May 25.

10.

Cancer vaccines: translation from mice to human clinical trials.

Maeng H, Terabe M, Berzofsky JA.

Curr Opin Immunol. 2018 Apr;51:111-122. doi: 10.1016/j.coi.2018.03.001. Epub 2018 Mar 16. Review.

11.

Possible Therapeutic Application of Targeting Type II Natural Killer T Cell-Mediated Suppression of Tumor Immunity.

Kato S, Berzofsky JA, Terabe M.

Front Immunol. 2018 Feb 22;9:314. doi: 10.3389/fimmu.2018.00314. eCollection 2018. Review.

12.

Cancer vaccine strategies: translation from mice to human clinical trials.

Berzofsky JA, Terabe M, Trepel JB, Pastan I, Stroncek DF, Morris JC, Wood LV.

Cancer Immunol Immunother. 2018 Dec;67(12):1863-1869. doi: 10.1007/s00262-017-2084-x. Epub 2017 Nov 15. Review.

13.

Glycolipid-peptide conjugate vaccines enhance CD8+ T cell responses against human viral proteins.

Speir M, Authier-Hall A, Brooks CR, Farrand KJ, Compton BJ, Anderson RJ, Heiser A, Osmond TL, Tang CW, Berzofsky JA, Terabe M, Painter GF, Hermans IF, Weinkove R.

Sci Rep. 2017 Oct 27;7(1):14273. doi: 10.1038/s41598-017-14690-5.

14.

Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity.

Leshem Y, O'Brien J, Liu X, Bera TK, Terabe M, Berzofsky JA, Bossenmaier B, Niederfellner G, Tai CH, Reiter Y, Pastan I.

Cancer Immunol Res. 2017 Aug;5(8):685-694. doi: 10.1158/2326-6066.CIR-16-0330. Epub 2017 Jul 3.

15.

Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy.

Terabe M, Robertson FC, Clark K, De Ravin E, Bloom A, Venzon DJ, Kato S, Mirza A, Berzofsky JA.

Oncoimmunology. 2017 Mar 31;6(5):e1308616. doi: 10.1080/2162402X.2017.1308616. eCollection 2017.

16.

Labeling Extracellular Vesicles for Nanoscale Flow Cytometry.

Morales-Kastresana A, Telford B, Musich TA, McKinnon K, Clayborne C, Braig Z, Rosner A, Demberg T, Watson DC, Karpova TS, Freeman GJ, DeKruyff RH, Pavlakis GN, Terabe M, Robert-Guroff M, Berzofsky JA, Jones JC.

Sci Rep. 2017 May 12;7(1):1878. doi: 10.1038/s41598-017-01731-2.

17.

Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients.

Castiello L, Sabatino M, Ren J, Terabe M, Khuu H, Wood LV, Berzofsky JA, Stroncek DF.

Clin Cancer Res. 2017 Jul 1;23(13):3352-3364. doi: 10.1158/1078-0432.CCR-16-2199. Epub 2017 Jan 10.

18.

Examination for Effectiveness of Scatter Correction in Portable Chest Radiography.

Ichikawa H, Ono T, Sawane Y, Terabe M, Yamaguchi M, Shimada H.

Nihon Hoshasen Gijutsu Gakkai Zasshi. 2016;72(12):1207-1215. doi: 10.6009/jjrt.2016_JSRT_72.12.1207. Japanese.

19.

TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer.

Wood LV, Fojo A, Roberson BD, Hughes MS, Dahut W, Gulley JL, Madan RA, Arlen PM, Sabatino M, Stroncek DF, Castiello L, Trepel JB, Lee MJ, Parnes HL, Steinberg SM, Terabe M, Wilkerson J, Pastan I, Berzofsky JA.

Oncoimmunology. 2016 Jul 1;5(8):e1197459. doi: 10.1080/2162402X.2016.1197459. eCollection 2016 Aug.

20.

[Pneumomediastinum Due to the Fracture of the Maxillary Antrum].

Nishikawa R, Morimoto Y, Hamaguchi T, Urata H, Terabe M, Miki C.

Kyobu Geka. 2016 Jun;69(6):457-9. Japanese.

PMID:
27246131
21.

Optical Characterization of Gold Nanoparticle Layers Formed on Plastic Microbeads.

Shiigi H, Fujita T, Shan X, Terabe M, Mihashi A, Yamamoto Y, Nagaoka T.

Anal Sci. 2016;32(3):281-5. doi: 10.2116/analsci.32.281.

22.

NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.

Ma C, Kesarwala AH, Eggert T, Medina-Echeverz J, Kleiner DE, Jin P, Stroncek DF, Terabe M, Kapoor V, ElGindi M, Han M, Thornton AM, Zhang H, Egger M, Luo J, Felsher DW, McVicar DW, Weber A, Heikenwalder M, Greten TF.

Nature. 2016 Mar 10;531(7593):253-7. doi: 10.1038/nature16969. Epub 2016 Mar 2.

23.

Tumor-induced CD11b(+) Gr-1(+) myeloid-derived suppressor cells exacerbate immune-mediated hepatitis in mice in a CD40-dependent manner.

Kapanadze T, Medina-Echeverz J, Gamrekelashvili J, Weiss JM, Wiltrout RH, Kapoor V, Hawk N, Terabe M, Berzofsky JA, Manns MP, Wang E, Marincola FM, Korangy F, Greten TF.

Eur J Immunol. 2015 Apr;45(4):1148-58. doi: 10.1002/eji.201445093. Epub 2015 Feb 23.

24.

NKT cell networks in the regulation of tumor immunity.

Robertson FC, Berzofsky JA, Terabe M.

Front Immunol. 2014 Oct 28;5:543. doi: 10.3389/fimmu.2014.00543. eCollection 2014. Review.

25.

CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy.

Soto-Pantoja DR, Terabe M, Ghosh A, Ridnour LA, DeGraff WG, Wink DA, Berzofsky JA, Roberts DD.

Cancer Res. 2014 Dec 1;74(23):6771-83. doi: 10.1158/0008-5472.CAN-14-0037-T. Epub 2014 Oct 8.

26.

[Usefulness of spatially adaptive noise reduction processing in computer-assisted diagnosis system for bone scintigraphy].

Ichikawa H, Onoguchi M, Okuda K, Kato T, Terabe M, Shimada H.

Nihon Hoshasen Gijutsu Gakkai Zasshi. 2014 May;70(5):461-6. Japanese.

27.

The immunoregulatory role of type I and type II NKT cells in cancer and other diseases.

Terabe M, Berzofsky JA.

Cancer Immunol Immunother. 2014 Mar;63(3):199-213. doi: 10.1007/s00262-013-1509-4. Epub 2014 Jan 3. Review.

28.

Cancer vaccines: 21st century approaches to harnessing an ancient modality to fight cancer.

Berzofsky JA, Wood LV, Terabe M.

Expert Rev Vaccines. 2013 Oct;12(10):1115-8. doi: 10.1586/14760584.2013.836906. No abstract available.

29.

β-mannosylceramide activates type I natural killer t cells to induce tumor immunity without inducing long-term functional anergy.

O'Konek JJ, Kato S, Takao S, Izhak L, Xia Z, Illarionov P, Besra GS, Terabe M, Berzofsky JA.

Clin Cancer Res. 2013 Aug 15;19(16):4404-11. doi: 10.1158/1078-0432.CCR-12-2169. Epub 2013 Jun 26.

30.

Artifacts caused by insufficient contrast medium filling during C-arm cone-beam CT scans: a phantom study.

Terabe M, Ichikawa H, Kato T, Koshida K.

Radiol Phys Technol. 2014 Jan;7(1):25-34. doi: 10.1007/s12194-013-0227-0. Epub 2013 Jun 18.

PMID:
23775309
31.

Balance is a key for happiness.

Izhak L, Berzofsky JA, Terabe M.

Oncoimmunology. 2013 May 1;2(5):e24211.

32.

Identification and enhancement of HLA-A2.1-restricted CTL epitopes in a new human cancer antigen-POTE.

Huang YH, Terabe M, Pendleton CD, Stewart Khursigara D, Bera TK, Pastan I, Berzofsky JA.

PLoS One. 2013 Jun 4;8(6):e64365. doi: 10.1371/journal.pone.0064365. Print 2013.

33.

Delicate balance among three types of T cells in concurrent regulation of tumor immunity.

Izhak L, Ambrosino E, Kato S, Parish ST, O'Konek JJ, Weber H, Xia Z, Venzon D, Berzofsky JA, Terabe M.

Cancer Res. 2013 Mar 1;73(5):1514-23. doi: 10.1158/0008-5472.CAN-12-2567. Epub 2013 Jan 14.

34.

Iterative estimation of coherent-scattering profiles from given positions by use of a single-direction beam.

Terabe M, Okamoto H, Koshida K.

Radiol Phys Technol. 2012 Jul;5(2):237-47. doi: 10.1007/s12194-012-0159-0. Epub 2012 May 27.

PMID:
22644625
35.

Strategies to use immune modulators in therapeutic vaccines against cancer.

Berzofsky JA, Terabe M, Wood LV.

Semin Oncol. 2012 Jun;39(3):348-57. doi: 10.1053/j.seminoncol.2012.02.002. Review.

36.

A novel combination immunotherapy for cancer by IL-13Rα2-targeted DNA vaccine and immunotoxin in murine tumor models.

Nakashima H, Terabe M, Berzofsky JA, Husain SR, Puri RK.

J Immunol. 2011 Nov 15;187(10):4935-46. doi: 10.4049/jimmunol.1102095. Epub 2011 Oct 17.

37.

KLF13 sustains thymic memory-like CD8(+) T cells in BALB/c mice by regulating IL-4-generating invariant natural killer T cells.

Lai D, Zhu J, Wang T, Hu-Li J, Terabe M, Berzofsky JA, Clayberger C, Krensky AM.

J Exp Med. 2011 May 9;208(5):1093-103. doi: 10.1084/jem.20101527. Epub 2011 Apr 11.

38.

IL-15 ex vivo overcomes CD4+ T cell deficiency for the induction of human antigen-specific CD8+ T cell responses.

Yu H, Tawab-Amiri A, Dzutsev A, Sabatino M, Aleman K, Yarchoan R, Terabe M, Sui Y, Berzofsky JA.

J Leukoc Biol. 2011 Jul;90(1):205-14. doi: 10.1189/jlb.1010579. Epub 2011 Apr 7.

39.

Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity.

O'Konek JJ, Illarionov P, Khursigara DS, Ambrosino E, Izhak L, Castillo BF 2nd, Raju R, Khalili M, Kim HY, Howell AR, Besra GS, Porcelli SA, Berzofsky JA, Terabe M.

J Clin Invest. 2011 Feb;121(2):683-94. doi: 10.1172/JCI42314. Epub 2011 Jan 18.

40.

Basic thinking on image anaylsis. 4. Phenomenon occurring in patients (interactions of X-ray with Matter).

Terabe M.

Nihon Hoshasen Gijutsu Gakkai Zasshi. 2010 Apr 20;66(4):379-84. No abstract available.

41.

Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques.

Sui Y, Zhu Q, Gagnon S, Dzutsev A, Terabe M, Vaccari M, Venzon D, Klinman D, Strober W, Kelsall B, Franchini G, Belyakov IM, Berzofsky JA.

Proc Natl Acad Sci U S A. 2010 May 25;107(21):9843-8. doi: 10.1073/pnas.0911932107. Epub 2010 May 10.

42.

Management of behavioral and psychological symptoms of dementia in long-term care facilities in Japan.

Kutsumi M, Ito M, Sugiura K, Terabe M, Mikami H.

Psychogeriatrics. 2009 Dec;9(4):186-95. doi: 10.1111/j.1479-8301.2009.00301.x.

43.

Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody.

Terabe M, Ambrosino E, Takaku S, O'Konek JJ, Venzon D, Lonning S, McPherson JM, Berzofsky JA.

Clin Cancer Res. 2009 Nov 1;15(21):6560-9. doi: 10.1158/1078-0432.CCR-09-1066. Epub 2009 Oct 27.

44.

Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells.

Takaku S, Terabe M, Ambrosino E, Peng J, Lonning S, McPherson JM, Berzofsky JA.

Int J Cancer. 2010 Apr 1;126(7):1666-74. doi: 10.1002/ijc.24961.

45.

Pathogenic roles of CD14, galectin-3, and OX40 during experimental cerebral malaria in mice.

Oakley MS, Majam V, Mahajan B, Gerald N, Anantharaman V, Ward JM, Faucette LJ, McCutchan TF, Zheng H, Terabe M, Berzofsky JA, Aravind L, Kumar S.

PLoS One. 2009 Aug 27;4(8):e6793. doi: 10.1371/journal.pone.0006793.

46.

The contrasting roles of NKT cells in tumor immunity.

Berzofsky JA, Terabe M.

Curr Mol Med. 2009 Aug;9(6):667-72. Review.

47.

The role of NKT cells in tumor immunity.

Terabe M, Berzofsky JA.

Adv Cancer Res. 2008;101:277-348. doi: 10.1016/S0065-230X(08)00408-9. Review.

48.

IL-15 expands unconventional CD8alphaalphaNK1.1+ T cells but not Valpha14Jalpha18+ NKT cells.

Terabe M, Tagaya Y, Zhu Q, Granger L, Roederer M, Waldmann TA, Berzofsky JA.

J Immunol. 2008 Jun 1;180(11):7276-86.

49.

Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17.

Nam JS, Terabe M, Kang MJ, Chae H, Voong N, Yang YA, Laurence A, Michalowska A, Mamura M, Lonning S, Berzofsky JA, Wakefield LM.

Cancer Res. 2008 May 15;68(10):3915-23. doi: 10.1158/0008-5472.CAN-08-0206.

50.

An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments.

Nam JS, Terabe M, Mamura M, Kang MJ, Chae H, Stuelten C, Kohn E, Tang B, Sabzevari H, Anver MR, Lawrence S, Danielpour D, Lonning S, Berzofsky JA, Wakefield LM.

Cancer Res. 2008 May 15;68(10):3835-43. doi: 10.1158/0008-5472.CAN-08-0215.

Supplemental Content

Loading ...
Support Center